Stryker Corporation reports developments as a global medical technology company serving MedSurg, Neurotechnology and Orthopaedics markets. Company news commonly covers operating results, organic sales trends, segment performance, dividends, shareholder-meeting activity and executive finance or investor-relations appointments.
Stryker updates also address portfolio expansion across medical devices, implants, instruments, operating-room equipment, neurotechnology and vascular solutions. Recent corporate activity includes the completed acquisition of Amplitude Vascular Systems, adding an intravascular lithotripsy platform for peripheral arterial disease to Stryker's peripheral vascular portfolio.
Stryker (NYSE:SYK) announced Spencer Stiles will become President and Chief Operating Officer effective January 1, 2026. Stiles, a 27-year Stryker veteran and current Group President of Orthopaedics and Spine since 2019, will lead global businesses, strategy, and mergers and acquisitions. Dylan Crotty will be promoted to Group President, Orthopaedics; Crotty has 27 years at Stryker and currently serves as President, Instruments.
The appointments emphasize internal succession, operational continuity, and leadership experience across Orthopaedics, MedSurg, and Neurotechnology.
Stryker (NYSE:SYK) reported third quarter 2025 results: net sales $6.06B (+10.3% reported, +9.6% constant currency) and organic net sales +9.5%. MedSurg & Neurotechnology sales rose 14.4%; Orthopaedics rose 3.9% (pro forma Orthopaedics +12.5% excluding a divestiture). Reported EPS was $2.22 (+2.8%) and adjusted EPS was $3.19 (+11.1%). Adjusted operating margin expanded 90 bps to 25.6%; reported operating margin was 18.7%. Management raised full-year 2025 guidance to organic net sales growth 9.8–10.2% and adjusted EPS of $13.50–$13.60. The results reflect acquisition activity, higher amortization, and increased long-term debt linked to recent transactions.
Stryker (NYSE:SYK) will showcase expanded trauma solutions at the Orthopaedic Trauma Association Annual Meeting, October 15–18, 2025 in Phoenix (booth #601).
The company highlighted extensions to its Pangea and T2 Alpha nailing and plating platforms, including a new T2 Alpha Humeral nail designed for simplicity and streamlined humeral fixation, plus a novel femur reconstruction fracture system that combines T2 Alpha and Pangea for complex native and periprosthetic femur fractures. Stryker emphasizes simplified instrumentation, enhanced stability, and workflow efficiency, and will offer hands-on demonstrations and expert conversations at its booth.
Stryker (NYSE:SYK) has scheduled its third quarter 2025 financial results announcement for October 30, 2025. The company will release its Q3 2025 earnings press release at 4:05 p.m. ET, followed by a webcast discussion at 4:30 p.m. ET.
The financial results will cover the quarter ending September 30, 2025. Investors can access the webcast through Stryker's Events & Presentations webpage, with an archive available two hours after the live call concludes.
Stryker (NYSE:SYK) announced the launch of its Incompass™ Total Ankle System at the 2025 AOFAS Annual Meeting in Savannah, Georgia. The FDA-cleared system is designed for patients with end-stage ankle arthritis, featuring an innovative implant with an enhanced instrument platform.
The system builds on Stryker's legacy designs, Infinity and Inbone, which have demonstrated five-year survivorship rates of 98% or higher. Key features include 3D-printed porous metal components for early bony ingrowth, intraoperative flexibility, and reduced procedural complexity. The development leveraged SOMA technology and analysis of over 80,000 Prophecy scans and 100,000 total ankle cases.
Stryker (NYSE:SYK), a leading medical technology company, has announced it will host an Investor Day on November 13, 2025, at 2:30 p.m. Eastern Time. The event will take place in Mahwah, New Jersey.
Investors and interested parties can access the event through a live audio webcast on Stryker's website. For those unable to attend live, a replay of the session will be made available in the Investor Relations section of www.stryker.com.
Stryker (NYSE:SYK), a leading medical technology company, announced its participation in the upcoming 2025 Wells Fargo Securities Healthcare Conference. The event will take place at the Encore Boston Harbor on September 4, 2025.
Andy Pierce, Group President of MedSurg and Neurotechnology, and Jason Beach, Vice President of Finance and Investor Relations, will engage in a Fireside Chat at 2:15 PM ET. Investors can access both the live webcast and replay through Stryker's website.
Stryker (NYSE:SYK) has announced a quarterly dividend declaration of $0.84 per share. The dividend will be paid on October 31, 2025, to shareholders of record as of September 30, 2025. This dividend represents a 5.0% increase compared to the previous year, while remaining consistent with the last quarter's payout.
Stryker (NYSE:SYK) reported strong Q2 2025 results with net sales increasing 11.1% to $6.0 billion. The company achieved significant organic growth of 10.2%, driven by a 9.7% increase in unit volume and 0.5% from higher prices. Adjusted EPS grew 11.4% to $3.13, while adjusted operating income margin improved 110 basis points to 25.7%.
The MedSurg and Neurotechnology segment led growth with 17.3% increased sales to $3.8 billion, while Orthopaedics segment sales grew 2.0% to $2.2 billion. Based on strong performance, Stryker raised its 2025 guidance, now expecting organic net sales growth of 9.5% to 10.0% and adjusted EPS of $13.40 to $13.60.
Inari Medical, a division of Stryker (NYSE:SYK), has launched the next-generation InThrill® Thrombectomy System, marking a significant advancement in small vessel and arteriovenous (AV) access thrombectomy procedures.
The new 8 French over-the-wire system features enhanced capabilities including increased radial force for better luminal wall apposition, offset single open mouth for optimized clot capture, internal struts for even clot distribution, and improved ergonomics. The first commercial case was successfully performed on May 19, 2025, at UPMC health care system by Dr. Joshua Pinter and Dr. Anish Ghodadra.